Previous studies indicate an intriguing connection between elevated acetylation of transcription factors such as FXR, SREBP-1c, and ChREBP, and increased lipogenic gene expressions20–22, which provides a therapeutic strategy for nonalcoholic fatty liver disease. Here, MLXIPL is linked to metabolic dysfunction-associated steatotic liver disease.